This is consistent with previous reports that advanced glycation of apoA-I impairs its anti-atherogenic properties [18], and is associated with decreased LCAT activity and coronary atherosclerotic plaque progression in patients with T2DM [19]. The gene discussed is LCAT; the disease is type 2 diabetes mellitus.